IRulya Therapeutics Inc. (IRLA)
NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRLA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $432.36M
- EPS (TTM)
- -$162.79
- Dividend yield
- None
- 52-week range
- 15.10 – 910.00
- Day range
- 38.92 – 42.00
- Volume / Avg
- 200.56K / 63.03K
- Beta
- —
- Shares outstanding
- 10.84M
52-week range
IRLA stock today
On Nov 20, IRLA ended the session at $39.88, shedding $0.06 (0.15%), versus the S&P 500's 3.70% decline. Volume was 3.2x the average at 200.56K shares, a sign of unusually heavy trading. At this level, IRLA sits near the bottom of its 52-week range of $15.10 to $910.00: 95.6% below the high and 164.1% above the low.
IRulya Therapeutics has posted a net loss over the last twelve months (EPS of -$162.79), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About IRulya Therapeutics
Company profileIRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells and consists of automated equipment, the RCL, a sterile single-use consumable treatment kit comprising medical device kits, syringe kits, and process solutions.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Brigette Roberts M.D.
- Headquarters
- New Haven, CT
- Employees
- 38
- IPO year
- 2019
- Website
- irulya.com
Financial highlights
Full financialsIRulya Therapeutics reported a net loss of $84.0 million, compared with a loss of $56.8 million a year earlier. Diluted earnings per share came in at -$1.68.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-83.98M | $-56.83M | $-31.39M | $-51.66M | $-89.94M |
| EPS (diluted) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$76.13+90.90%
- Strong buy 2
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-1.12 vs $-0.84
- Surprise
- -33.33%
IRLA news
All IRLA newsIRulya Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PROKProKidney Corp. Class A | 1.04 | -1.89% | $415.21M | vs IRLA |
| TECXTectonic Therapeutic Inc. | 20.73 | -1.47% | $405.26M | vs IRLA |
| TVGNTevogen Inc. | 5.90 | -6.35% | $405.20M | vs IRLA |
| FENCFennec Pharmaceuticals Inc. | 13.09 | -2.68% | $462.14M | vs IRLA |
| CADLCandel Therapeutics Inc. | 5.04 | -1.75% | $395.37M | vs IRLA |
| RGNXREGENXBIO Inc. | 7.16 | -0.28% | $473.44M | vs IRLA |
| SANASana Biotechnology Inc. | 1.59 | -8.62% | $476.42M | vs IRLA |
| DNAGinkgo Bioworks Holdings Inc. Class A | 7.46 | -9.02% | $483.54M | vs IRLA |
Indexes, lists and sector
IRulya Therapeutics stock FAQ
What is IRulya Therapeutics's stock price today?
IRLA last traded at $39.88 as of Nov 20, 4:00 PM EST, down 0.15% on the day. Prices are delayed at least 15 minutes.
Who is IRulya Therapeutics's CEO?
Dr. Brigette Roberts M.D. is the chief executive officer of IRulya Therapeutics Inc., which has about 38 employees.
What is the IRLA 52-week high?
The 52-week high for IRLA is $910.00 and the 52-week low is $15.10. The stock is currently 95.6% below its high.